Published in Am J Pathol on August 01, 1993
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A (2004) 1.06
Adhesion receptors of the immune system. Nature (1990) 28.86
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell (1985) 7.29
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 6.38
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell (1986) 5.13
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol (1985) 4.76
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (1985) 4.66
Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol (1985) 3.69
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24
Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res (1981) 2.39
Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis (1989) 1.99
Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature (1985) 1.86
Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer (1977) 1.84
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood (1988) 1.72
Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol (1989) 1.65
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood (1988) 1.19
Localization of the human JUN protooncogene to chromosome region 1p31-32. Proc Natl Acad Sci U S A (1988) 1.10
Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG. Cell Immunol (1990) 1.06
Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice. Am J Pathol (1990) 0.99
Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res (1991) 0.98
Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte grafts. Cancer Res (1992) 0.97
Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro. J Virol (1992) 0.87
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
A requirement for two cell types for antibody formation in vitro. Science (1967) 8.91
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity (1995) 5.96
Extra-intestinal manifestations of salmonella infections. Medicine (Baltimore) (1987) 4.77
Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol (1987) 4.49
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Cell interactions in the primary immune response in vitro: a requirement for specific cell clusters. J Exp Med (1969) 3.38
Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 3.10
Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J Exp Med (1985) 2.87
Activation of mouse lymphocytes by anti-immunoglobulin. I. Parameters of the proliferative response. J Exp Med (1978) 2.86
Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol (1987) 2.83
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity (1999) 2.67
Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A (1987) 2.56
Surface immunoglobulin D as a functional receptor for a subclass of B lymphocytes. Immunol Rev (1977) 2.50
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci U S A (1997) 2.50
Ontogeny of mouse lymphocyte function. II. Development of the ability to produce antibody is modulated by T lymphocytes. J Exp Med (1975) 2.49
Cytomegalovirus infection in the normal host. Medicine (Baltimore) (1985) 2.34
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 2.28
The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A (1998) 2.22
Inability of mice with a defect in B-lymphocyte maturation to respond to phosphorycholine on immunogenic carriers. J Exp Med (1977) 2.18
T-independent responses in B cell-defective CBA/N mice to Brucella abortus and to trinitrophenyl (TNP) conjugates of Brucella abortus. Eur J Immunol (1978) 2.13
The rate of division of antibody-forming cells during the early primary immune response. J Exp Med (1968) 2.10
Cellular requirements for the primary in vitro antibody response to DNP-ficoll. J Exp Med (1974) 2.10
Varicella-zoster virus open reading frame 61 protein is functionally homologous to herpes simplex virus type 1 ICP0. J Virol (1992) 2.09
CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). J Exp Med (1988) 2.06
The ontogeny of thymic independent antibody responses in vitro in normal mice and mice with an X-linked B cell defect. J Immunol (1977) 2.03
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol (2006) 2.00
Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J Exp Med (1987) 2.00
The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol (1996) 1.93
NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 1.92
Anti-idiotype induced regulation of helper cell function for the response to phosphorylcholine in adult BALB/c mice. J Exp Med (1978) 1.89
Collaboration: a concept analysis. J Adv Nurs (1995) 1.89
Mice whose B cells cannot produce the T15 idiotype also lack an antigen-specific helper T cell required for T15 expression. J Exp Med (1979) 1.86
In vitro responses of CBA/N mice: spleen cells of mice with an X-linked defect that precludes immune responses to several thymus-independent antigens can respond to TNP-lipopolysaccharide. J Immunol (1976) 1.86
Functional maturation of thymic lymphocyte populations in vitro. J Exp Med (1972) 1.76
Varicella-zoster virus open reading frame 10 protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus immediate-early gene promoters. J Virol (1993) 1.71
Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virology (1994) 1.70
Absence of an antigen-specific helper T cell required for the expression of the T 15 idiotype in mice treated with anti-mu antibody. Eur J Immunol (1980) 1.62
Primary in vitro antibody responses by purified murine B lymphocytes in serum-free defined medium. J Immunol (1981) 1.61
Cellular deficit in thymectomized mice. Nature (1970) 1.57
Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro. J Immunol (1985) 1.55
Varicella-zoster virus open reading frame 4 protein is functionally distinct from and does not complement its herpes simplex virus type 1 homolog, ICP27. J Virol (1994) 1.52
A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity (1998) 1.52
Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol (2001) 1.51
Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc Natl Acad Sci U S A (1998) 1.50
In vitro studies of the genetically determined unresponsiveness to thymus-independent antigens in CBA/N mice. J Immunol (1976) 1.50
The role of surface IgD in the response to thymic-independent antigens. J Exp Med (1977) 1.46
The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J Virol (1998) 1.46
Infection of human T lymphocytes with varicella-zoster virus: an analysis with viral mutants and clinical isolates. J Virol (2000) 1.46
Varicella-zoster virus (VZV) open reading frame 61 protein transactivates VZV gene promoters and enhances the infectivity of VZV DNA. J Virol (1993) 1.45
Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin Immunol (2001) 1.44
The rat ventral island flap: a comparison of the effects of reduction in arterial inflow and venous outflow. Plast Reconstr Surg (1996) 1.44
Lyb-7, a new B cell alloantigen controlled by genes linked to the IgCH locus. J Immunol (1979) 1.43
Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol (2000) 1.42
Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J Infect Dis (2000) 1.40
Ontogeny of mouse lymphocyte function. I. Paradoxical elevation of reactivity to allogeneic cells and phytohemagglutinin in BALB-c fetal thymocytes. J Immunol (1974) 1.39
Activation of mouse lymphocytes by anti-immunoglobulin. II. A thymus-independent response by a mature subset of B lymphocytes. J Exp Med (1978) 1.37
Unilateral parathyroid exploration. Arch Otolaryngol Head Neck Surg (1998) 1.37
Proteins and cis-acting elements associated with transactivation of the varicella-zoster virus (VZV) immediate-early gene 62 promoter by VZV open reading frame 10 protein. J Virol (1995) 1.36
Animal models for retrovirus-induced immunodeficiency disease. Immunol Invest (1986) 1.34
Ly phenotype and mechanism of action of mouse neonatal suppressor T cells. J Exp Med (1977) 1.33
Disruption of the varicella-zoster virus dUTPase and the adjacent ORF9A gene results in impaired growth and reduced syncytia formation in vitro. Virology (1997) 1.32
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 1.32
Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol Head Neck Surg (1994) 1.31
hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol Rev (1991) 1.29
The varicella-zoster virus ORF66 protein induces kinase activity and is dispensable for viral replication. J Virol (1996) 1.29
Herpesvirus saimiri open reading frame 14, a protein encoded by T lymphotropic herpesvirus, binds to MHC class II molecules and stimulates T cell proliferation. J Immunol (1996) 1.25
Adoptive transfer of neonatal T lymphocytes rescues immunoglobulin production in mice with severe combined immune deficiency. J Exp Med (1991) 1.23
The murine gammaherpesvirus-68 M11 protein inhibits Fas- and TNF-induced apoptosis. J Gen Virol (1999) 1.21
Role of a nonimmunoglobulin cell surface determinant in the activation of B lymphocytes by thymus-independent antigens. J Exp Med (1979) 1.19
Macrophage requirement for the in vitro response to TNP Ficoll: a thymic independent antigen. J Immunol (1976) 1.19
HIV results in the frame. CD4+ cell turnover. Nature (1995) 1.19
Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proc Natl Acad Sci U S A (1988) 1.18
Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro. J Virol (1994) 1.17
The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes. J Virol (1998) 1.15
Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J Virol (2001) 1.15
Autoantibody production by severe combined immunodeficient mice reconstituted with synovial cells from rheumatoid arthritis patients. Eur J Immunol (1990) 1.14
Induction of B lymphocyte proliferation by monoclonal anti-Lyb 2 antibody. J Immunol (1983) 1.11
Varicella-zoster virus ORF57, unlike its pseudorabies virus UL3.5 homolog, is dispensable for viral replication in cell culture. Virology (1998) 1.10
Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. J Infect Dis (1998) 1.10
The RING finger domain of the varicella-zoster virus open reading frame 61 protein is required for its transregulatory functions. Virology (1994) 1.09
Varicella-zoster virus (VZV) ORF32 encodes a phosphoprotein that is posttranslationally modified by the VZV ORF47 protein kinase. J Virol (1998) 1.08
The immunoglobulin allotype contributed by peritoneal cavity B cells dominates in SCID mice reconstituted with allotype-disparate mixtures of splenic and peritoneal cavity B cells. J Exp Med (1990) 1.07
Activation of B lymphocytes by monovalent anti-Lyb-2 antibodies. J Exp Med (1984) 1.04
Molecular mechanisms of antiviral resistance. Antiviral Res (1995) 1.03
Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol (2009) 1.02
Specific H chain junctional diversity may be required for non-T15 antibodies to bind phosphorylcholine. J Immunol (1988) 1.01
Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol (1997) 1.01
Studies of HIV infection and the development of Epstein-Barr virus-related B cell lymphomas following transfer of human lymphocytes to mice with severe combined immunodeficiency. Curr Top Microbiol Immunol (1989) 1.01
Formation of antibody in the newborn mouse: study of T-cell-independent antibody response. J Infect Dis (1977) 1.00
Immunologic effects of neonatal infection with mouse thymic virus. J Immunol (1975) 1.00
Lyb antigens and their role in B lymphocyte activation. Immunol Rev (1982) 0.99
Ex situ conservation of plant genetic resources: global development and environmental concerns. Science (1991) 0.99
The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. J Immunol (1999) 0.98
Expression of a uracil DNA glycosylase (UNG) inhibitor in mammalian cells: varicella-zoster virus can replicate in vitro in the absence of detectable UNG activity. Virology (1998) 0.98